ImmunoGen at ESMO: Full Data from Phase 3 Trial in Ovarian Cancer Misses Endpoint

FORWARD I Did Not Meet Primary Endpoint of Progression-Free Survival; Promising Efficacy Results Seen in Folate Receptor Alpha (FRα) High Patients

Favorable Tolerability and Differentiated Safety Profile Observed with Mirvetuximab Monotherapy Compared to Chemotherapy

Exploratory Analyses Demonstrate Improved Efficacy Outcomes in FRα High Patients

Registration Study for Mirvetuximab in Ovarian Cancer on Track to Start by Year-End

Conference Call to be Held Monday, September 30 at 8:00 a.m. ET

https://www.marketscreener.com/IMMUNOGEN-INC-9667/news/ImmunoGen-Presents-Full-Data-from-Phase-3-FORWARD-I-Study-of-Mirvetuximab-Soravtansine-in-Ovarian-29274504/